What is the effect of taking the targeted drug ivonib (ivitinib) for advanced cholangiocarcinoma?

For advanced cholangiocarcinoma, the clinical efficacy of taking the targeted drug Ivonib (Ivitinib, Tibsovo) is significant. Ivonib is a potent oral targeted inhibitor targeting cancers with IDH1 gene mutations.

According to data from the ClarIDHy clinical trial, ivonib has shown significant efficacy in the treatment of patients with advanced cholangiocarcinoma carrying IDH1 mutations. Avosidenib reduced the risk of disease progression and death by 63% compared with placebo (hazard ratio HR=0.37, 95% an>Confidence intervalCI is 0.25-0.54, p<0.001). This data shows that ivosidenib can significantly extend the progression-free survival of patients.

Specifically, the median progression-free survival was 2.7 months in the ivonib group, compared with 1.4 months in the placebo group. In addition, the progression-free survival rates of patients in the ivonib group were 6 months and 12 months respectively. % and 22%, whereas all patients in the placebo group experienced disease progression or died after 6 months. These data demonstrate the superior efficacy of ivonib in extending progression-free survival in patients with advanced cholangiocarcinoma.

In addition to progression-free survival, ivosidenib also had a positive impact on patients' overall survival. Although due to the provisions of the clinical trial protocol, patients randomly assigned to the placebo group can be transferred to the treatment group after disease progression, resulting in the difference in overall survival (OS) not reaching statistically significant standards, the ivonib treatment group The median OS still reached 10.3 months, which was higher than the 7.5 in the placebo group.Months. This trend suggests that ivosidenib has the potential to extend overall survival in patients.

In clinical trials, avosidenib demonstrated good tolerability and safety. Avosidenib is well tolerated by patients and most of the adverse reactions are controllable. This means that Avonib is not only effective, but also relatively safe during use, providing patients with a better treatment experience.

Avosidenib, as an oral drug, brings great convenience to patients. Compared with traditional chemotherapy drugs that require intravenous injection, oral drugs are easier to administer and use, helping to improve patients' treatment compliance. The recommended dosage is 500mg taken orally daily, which can be adjusted according to the patient's physical condition and drug tolerance.

Cholangiocarcinoma is a rare and aggressive cancer, and IDH1 mutations occur in approximately 13% of patients with cholangiocarcinoma. As the first targeted therapy approved for the treatment of patients with advanced cholangiocarcinoma harboring IDH1 mutations, ivonib fills a therapeutic gap in this field. Its emergence provides new treatment options for these patients and is expected to improve their quality of life and prognosis.

The clinical efficacy of ivonib is not only reflected in the treatment of individual patients, but also provides reference and inspiration for the treatment of other rare and refractory diseases, promoting the development of precision medicine and personalized treatment. Secondly, the launch and widespread application of ivonib will help increase public awareness and concern about rare diseases such as cholangiocarcinoma, and promote investment in related medical resources and R&D innovation. Finally, ivonib brings hope of life to patients with advanced cholangiocarcinoma, improves their quality of life, and reduces the burden on families and society.